Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer (NCT05705401)

🧪 Interventions in This Study

• Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (418 Sites)

Showing the first 25 of 418 sites.

• Cancer Center at Saint Joseph's — Phoenix, Arizona
• Banner University Medical Center - Tucson — Tucson, Arizona
• University of Arizona Cancer Center-North Campus — Tucson, Arizona
• NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
• Kaiser Permanente-Deer Valley Medical Center — Antioch, California
• Mission Hope Medical Oncology - Arroyo Grande — Arroyo Grande, California
• PCR Oncology — Arroyo Grande, California
• Sutter Auburn Faith Hospital — Auburn, California
• Sutter Cancer Centers Radiation Oncology Services-Auburn — Auburn, California
• Tower Cancer Research Foundation — Beverly Hills, California
• Sutter Cancer Centers Radiation Oncology Services-Cameron Park — Cameron Park, California
• City of Hope Comprehensive Cancer Center — Duarte, California
• Kaiser Permanente Dublin — Dublin, California
• Kaiser Permanente-Fremont — Fremont, California
• Palo Alto Medical Foundation-Fremont — Fremont, California
• Fresno Cancer Center — Fresno, California
• Kaiser Permanente-Fresno — Fresno, California
• UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
• City of Hope at Irvine Lennar — Irvine, California
• City of Hope Antelope Valley — Lancaster, California
• Los Angeles General Medical Center — Los Angeles, California
• USC / Norris Comprehensive Cancer Center — Los Angeles, California
• Cedars Sinai Medical Center — Los Angeles, California
• Memorial Medical Center — Modesto, California
• Kaiser Permanente-Modesto — Modesto, California

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in HER2-positive Breast Cancer

• Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease — Tampa, Florida
• Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] — Los Angeles, California
• ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer — Plantation, Florida
• PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer — Boston, Massachusetts
• A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer — Mobile, Alabama
• A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer — Stamford, Connecticut

Explore by condition: All HER2-positive Breast Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.